Clinical Trials Browser

Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Nausea, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms

NCT00343863 2017-07-11

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Phase NA Completed

41 enrolled 12 charts

Breast

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male

NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Phase 2 Completed

54 enrolled 7 charts

Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

NCT00895245 2017-05-18

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Phase 2 Terminated

6 enrolled 5 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nausea, Vomiting

NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

Phase 2 Completed

20 enrolled 8 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT02203253 2016-08-24

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

Phase 3 Completed

642 enrolled

Neoplasms, Vomiting

NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Phase 2 Unknown

80 enrolled

Thoracic

Lung Neoplasms, Nausea, Vomiting

NCT00475085 2015-11-10

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Phase 3 Completed

1,021 enrolled 10 charts

Breast

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT01074697 2015-04-24

GAND-emesis

Phase 3 Completed

246 enrolled

Genital Neoplasms, Female, Nausea, Vomiting

NCT01046240 2015-01-27

Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy

Phase 1/2 Completed

29 enrolled

Vomiting

NCT02290470 2014-11-14

Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

Phase 2 Unknown

81 enrolled

Nausea, Vomiting

NCT00636805 2014-04-01

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

Phase 2 Terminated

63 enrolled 11 charts

CNS

Brain Neoplasms

NCT01640340 2013-11-07

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Phase NA Completed

40 enrolled 12 charts

Tumor-Agnostic

Neoplasms

NCT00410488 2013-03-22

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Phase NA Completed

51 enrolled 5 charts

Sarcoma

Nausea, Sarcoma, Vomiting

NCT01481831 2012-12-31

ESPNV

Phase 4 Completed

599 enrolled

Neoplasms, Vomiting

NCT01031498 2012-08-07

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Phase 2 Completed

150 enrolled 7 charts

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Nausea, Vomiting, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00412425 2012-05-04

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

Phase 1/2 Completed

30 enrolled 4 charts

Dermatologic

Anorexia, Melanoma, Nausea, Vomiting, Weight Loss

NCT01018758 2009-11-25

NHLPal

Phase 2 Completed

86 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Vomiting

NCT00415103 2009-09-18

AMENO-2

Phase 4 Completed

196 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nausea, Vomiting

NCT00666783 2008-04-25

An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

Phase 2 Completed

208 enrolled

Vomiting

Clinical Trials

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

ProTreat

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

CINV

TSEPHCC

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

MEDEA

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

GIM15-NEPA

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

RAPA

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Multi-day Doses in Prevention of Nausea and Emesis

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

GAND-emesis

Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy

Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

ESPNV

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

NHLPal

AMENO-2

An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients